Krispy Kreme Inc vs Illumina, Inc. — how do they compare? Krispy Kreme Inc trades at $3.01 (market cap $508.36M), while Illumina, Inc. trades at $264.24 (market cap $40.43B). The key difference: Illumina, Inc. is far larger — about 79.5× Krispy Kreme Inc's market cap, and Krispy Kreme Inc pays a 3.47% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Krispy Kreme Inc for 45 Days and Illumina, Inc. for 83 Days on average.
| DNUT | ILMN | |
|---|---|---|
Market Cap | $508.36M | $40.43B |
Volume | 1,955,706 | 2,948,626 |
Sector | Consumer Staples | Health |
52-Week High | $4.70 | $293.69 |
52-Week Low | $2.87 | $91.00 |
Typical Hold Time | 45 Days | 83 Days |
Enterprise Value | $1.75B | $41.79B |
Dividend Yield | 3.47% | — |
Signals from Pluang's Aura AI — not financial advice
Krispy Kreme (DNUT) trades at $3.01, down 0.33% on the day, with a bearish technical signal. The company reported a net loss of $515.77 million in 2025, despite a 75.19% gross margin, and faces legal investigations into fiduciary duties. Revenue declined to $1.52 billion in 2025 from $1.7 billion in 2024.
The outlook is cautious due to persistent losses and legal overhangs, though analyst consensus leans buy. Key risks include profitability challenges and high debt. Upside depends on operational turnaround and new product launches driving growth.
Illumina (ILMN) trades at $264.40, down 3.34% on the day but up significantly year-to-date with strong technical momentum. The stock shows bullish moving average signals and trades near pivot point resistance at $268. Fundamentally, the company has delivered three consecutive quarterly earnings beats and returned to profitability in 2025 with $850 million net income after previous losses. Recent catalysts include S&P 500 inclusion effective September 21, 2026, and growing AI integration in genomics applications.
The outlook remains positive with analyst consensus favoring Buy ratings (54%) and a $241 price target, though current price exceeds consensus. Key opportunities include sequencing growth and AI-driven biological data expansion, while risks involve China market headwinds and elevated valuation multiples. Earnings growth and S&P 500 inclusion provide near-term catalysts, but the stock trades at premium valuations with P/E of 49.96 requiring sustained execution.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Krispy Kreme Inc is a sweet treat brands company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in- your-mouth experience. It operates in 30 countries through its network of fresh Doughnut Shops, partnerships with retailers, and a growing ecommerce and delivery business. The company conducts its business through the following three reported segments namely U.S. and Canada, includes all operations in the U.S. and Canada, Insomnia Cookies shops, and the Branded Sweet Treat Line
Read more on DNUT →Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →